Perspective Therapeutics(NYSEMKT) CATX

Perspective Therapeutics, Inc. makes targeted treatments for cancer. These therapies help doctors find and kill tumor cells directly. They solve problems for patients with serious malignant conditions.

Tools for Targeting Cancer

• Brachytherapy Seeds: Cesium-131 seeds used for internal radiation treatment in patients with various solid tumors.
• Therapeutic Candidates: Investigational drugs using Lead-212, an alpha-emitting isotope, to deliver radiation directly to cancer cells.
• Imaging Solutions: Techniques that allow doctors to visualize tumors before delivering targeted radiation therapy.
• Generator Platform: Proprietary technology for manufacturing clinical drug candidates at the company’s regional facilities.

Expansion and Strategic Alliances

• Acquired a manufacturing facility in Somerset, New Jersey, from Lantheus in 2024 to increase production capacity.
• Entered a clinical trial collaboration with Bristol Myers Squibb in March 2024 to study combination therapies.
• Purchased three buildings in Houston, Chicago, and Los Angeles during 2024 for future manufacturing use.
• Secured Thorium-228 supply agreements with the U.S. Department of Energy in 2025 and 2026.

How Does Perspective Stand Out?

Perspective integrates imaging and therapy into a single theranostic approach, which is a combination of therapy and diagnostics, to improve patient outcomes. Its growing U.S. manufacturing footprint reduces reliance on external suppliers for clinical drug delivery.

Tracking the Financial Path

• Cash, cash equivalents, and short-term investments totaled $236.9 million as of June 30, 2026.
• Operating loss was $57.5 million for the six months ended June 30, 2026.
• Research and development expenses reached $42.9 million for the six-month period ended June 30, 2026.
• Perspective raised approximately $175.0 million in gross proceeds through an offering on Feb. 3, 2026.

The Path Forward

Perspective has evolved from a medical device maker into a clinical-stage radiopharmaceutical developer. Its investments in specialized infrastructure and clinical trials define its current growth strategy.